Search

Displaying results 4251 - 4260 of 7603 in total
  1. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

  2. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression.

  3. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). It was generated by HGS usin...

  4. Drug

    Hydrotalcite

    go.drugbank.com/drugs/DB13322
    ApprovedInvestigationalWithdrawn

    Categories: Drugs for Acid Related Disorders
  5. Drug

    99mTc-glucarate

    go.drugbank.com/drugs/DB05810
    Investigational

    99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.

  6. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  7. Drug

    MEM 1414

    go.drugbank.com/drugs/DB05888
    Experimental

    MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.

  8. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

  9. Drug

    Creatinolfosfate

    go.drugbank.com/drugs/DB13071
    Investigational

    COP has been investigated for the treatment of Diabetic Retinopathy. … COP is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory Degenerative Joint Disease.

  10. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    It is being considered for treatment of stress-related urinary incontinence. … Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.